MALCOLM BRENNER to Mice
This is a "connection" page, showing publications MALCOLM BRENNER has written about Mice.
Connection Strength
0.883
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.045
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.044
-
Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. Mol Ther. 2015 Sep; 23(9):1497-506.
Score: 0.038
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.038
-
An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells. Mol Ther. 2015 Sep; 23(9):1475-85.
Score: 0.038
-
T cell receptors and cancer: gain gives pain. Nat Med. 2010 May; 16(5):520-1.
Score: 0.027
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Aug; 26(8):858-868.
Score: 0.017
-
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
Score: 0.016
-
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy. J Immunother Cancer. 2023 04; 11(4).
Score: 0.016
-
Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.
Score: 0.016
-
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
Score: 0.016
-
Is retroviral gene marking too dangerous to use? Cytotherapy. 2003; 5(3):190-3.
Score: 0.016
-
Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood. 2003 Mar 15; 101(6):2434-9.
Score: 0.016
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.016
-
Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. Blood. 2002 Jul 01; 100(1):200-7.
Score: 0.015
-
Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002 Mar; 5(3):233-41.
Score: 0.015
-
Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas. J Immunother Cancer. 2021 05; 9(5).
Score: 0.014
-
Transgenic CD8a? co-receptor rescues endogenous TCR function in TCR-transgenic virus-specific T cells. J Immunother Cancer. 2020 11; 8(2).
Score: 0.014
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.014
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.013
-
Single-cell transcriptomics identifies multiple pathways underlying antitumor function of TCR- and CD8a?-engineered human CD4+ T cells. Sci Adv. 2020 07; 6(27):eaaz7809.
Score: 0.013
-
"Resistance is futile". Gene Ther. 1999 Oct; 6(10):1646-7.
Score: 0.013
-
Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun; 23(6):549-57.
Score: 0.012
-
Nonlethal detection of transgene expression in the CNS of founder mice. Biotechniques. 1999 Feb; 26(2):302-4, 306-7.
Score: 0.012
-
Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice. Nat Med. 1998 Nov; 4(11):1253-60.
Score: 0.012
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.012
-
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
Score: 0.012
-
Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997 Nov 01; 8(16):1935-43.
Score: 0.011
-
c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood. 2017 12 21; 130(25):2739-2749.
Score: 0.011
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.011
-
Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. Mol Ther. 2017 11 01; 25(11):2440-2451.
Score: 0.011
-
CD40 ligand induces an antileukemia immune response in vivo. Blood. 1997 Sep 01; 90(5):1927-33.
Score: 0.011
-
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. Cancer Discov. 2017 11; 7(11):1238-1247.
Score: 0.011
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.011
-
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
Score: 0.011
-
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther. 2017 01 04; 25(1):249-258.
Score: 0.011
-
A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood. 1997 Jan 01; 89(1):119-27.
Score: 0.011
-
Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996 Oct; 2(10):1090-5.
Score: 0.010
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.010
-
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. Mol Ther. 2016 Jun; 24(6):1135-1149.
Score: 0.010
-
Somatostatin as a trophic factor. Analysis of transgenic mice overexpressing somatostatin in astrocytes. Ann N Y Acad Sci. 1996 Mar 22; 780:29-35.
Score: 0.010
-
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18; 125(25):3905-16.
Score: 0.009
-
Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. Cancer Gene Ther. 2014 Nov; 21(11):472-482.
Score: 0.009
-
Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
Score: 0.009
-
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014 Jan 01; 20(1):131-9.
Score: 0.008
-
Mouse models in bone marrow transplantation and adoptive cellular therapy. Semin Hematol. 2013 Apr; 50(2):131-44.
Score: 0.008
-
Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol. 1992 Jun; 81(2):231-4.
Score: 0.008
-
Graft-versus-host reactions and bone-marrow transplantation. Curr Opin Immunol. 1991 Oct; 3(5):752-7.
Score: 0.007
-
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother. 2010 Oct; 33(8):780-8.
Score: 0.007
-
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol. 2010 Oct 01; 185(7):4223-32.
Score: 0.007
-
Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010 Sep; 12(5):576-8.
Score: 0.007
-
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. Stem Cells. 2010 Jun; 28(6):1107-15.
Score: 0.007
-
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010 Jun; 24(6):1160-70.
Score: 0.007
-
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009 Nov 26; 114(23):4784-91.
Score: 0.006
-
Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009 Sep 15; 15(18):5852-60.
Score: 0.006
-
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18; 113(25):6392-402.
Score: 0.006
-
Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther. 2009 May; 17(5):880-8.
Score: 0.006
-
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother. 2008 Jun; 31(5):500-5.
Score: 0.006
-
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007 Oct 15; 110(8):2793-802.
Score: 0.005
-
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. Cancer Gene Ther. 2007 Oct; 14(10):819-27.
Score: 0.005
-
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007 Oct 01; 110(7):2620-30.
Score: 0.005
-
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol. 2007 Feb; 170(2):620-32.
Score: 0.005
-
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006 Dec 01; 108(12):3890-7.
Score: 0.005
-
Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006 May-Jun; 29(3):250-60.
Score: 0.005
-
An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005 Jun 01; 105(11):4247-54.
Score: 0.005
-
Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004 Oct 15; 104(8):2432-40.
Score: 0.004
-
Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids. Mol Ther. 2004 Apr; 9(4):489-95.
Score: 0.004
-
An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res. 2004 Mar; 28(3):295-9.
Score: 0.004
-
Primitive adult hematopoietic stem cells can function as osteoblast precursors. Proc Natl Acad Sci U S A. 2003 Dec 23; 100(26):15877-82.
Score: 0.004
-
Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther. 2003 Jun; 7(6):748-54.
Score: 0.004
-
Cells of the hepatic side population contribute to liver regeneration and can be replenished with bone marrow stem cells. Haematologica. 2003 Apr; 88(4):368-78.
Score: 0.004
-
hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis. 2001 Oct; 31(2):85-94.
Score: 0.004
-
A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
Score: 0.004
-
Inhibition of glioma cells in vitro and in vivo using a recombinant adenoviral vector containing an astrocyte-specific promoter. Cancer Gene Ther. 2000 Aug; 7(8):1120-6.
Score: 0.003
-
Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood. 1999 Sep 15; 94(6):1906-14.
Score: 0.003
-
European School of Oncology position paper. Gene therapy for the medical oncologist. Eur J Cancer. 1995; 31A(9):1531-7.
Score: 0.002
-
T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 1986 Dec; 103(2):476-80.
Score: 0.001
-
Immunofluorescent studies of human leukemic cells with antiserum to a murine leukemic virus (Rauscher strain). Blood. 1968 Mar; 31(3):381-7.
Score: 0.000